Status:
COMPLETED
Safety, Tolerability and Pharmacokinetics of Liraglutide-depot in Healthy Subjects
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 2
Eligibility:
MALE
18-55 years
Phase:
PHASE1
Brief Summary
This trial is conducted in the United States of America (USA). The aim of this trial is to investigate the safety, tolerability and pharmacokinetics (exposure in the body) of liraglutide-depot in heal...
Eligibility Criteria
Inclusion
- Body mass index (BMI) between 20 and 35 kg/m\^2 (both inclusive) with a body weight of at least 60 kg
- Apart from being obese (BMI above 30 kg/m\^2) the subject has to be considered generally healthy
Exclusion
- Medical history of, or presence of, cancer, diabetes or any clinically significant cardiovascular, respiratory, metabolic, renal, hepatic, gastrointestinal, endocrine, haematological, dermatological, venereal, neurological, psychiatric diseases or other major disorders
- Clinical or laboratory findings which suggest that the subject cannot be considered generally healthy
- Prescription medicine and non-prescription medicine with few exceptions
- Current and prior history of alcohol or drug abuse
- Current smoking of more than 5 cigarettes per day
- Mental incapacity, language barriers, or unwillingness to comply with the protocol
Key Trial Info
Start Date :
October 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2012
Estimated Enrollment :
31 Patients enrolled
Trial Details
Trial ID
NCT01473953
Start Date
October 1 2011
End Date
March 1 2012
Last Update
March 23 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Evansville, Indiana, United States, 47710